Merger Speculation Lifts Large-Cap Pharma Stocks Amid M&A Rumors
The recent merger speculation surrounding AstraZeneca and Bristol Myers Squibb has pushed large-cap pharmaceutical stocks back into the spotlight.
AstraZeneca's intraday fall of up to 7% and a 6% premarket jump for Bristol Myers demonstrate how quickly sentiment can shift when potential mega deals hit the headlines.
The article highlights three stocks from the healthcare sector that are exposed to this news and appear positively positioned based on current catalysts: GSK, Eli Lilly, and Johnson & Johnson.
GSK stands out for its scale, broad vaccine and specialty medicine portfolio, active oncology pipeline, and a P/E of 16x well below peers. Management is investing in R&D with over 20 Phase III starts in 2026 and targeting £1.9b in cost savings to support margins.
Eli Lilly's accelerating GLP-1 story commands a premium due to its rich pipeline, but the real tension lies between its high P/E and potential growth if capacity, pricing, and Medicare all shift together.